- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- ASTRAZENECA PHARMA INDIA LIMITED (pharmaceuticals)
- ASTRAZENECA PHARMA INDIA LIMITED Financial Data
ASTRAZENECA PHARMA Fact Sheet 
(AIDL)
Here is the latest financial fact sheet of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA quarterly results and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
ASTRAZENECA PHARMA Price History
| % ch | % | 3.4 |
| No. of shares | m | 25.00 |
| % ch week | % | 1.7 |
| % ch 1-mth | % | 26.0 |
| % ch 12-mth | % | 95.0 |
| 52 week H/L | Rs | 1,823.4/882.6 |
ASTRAZENECA PHARMA Financials
| No. of Mths Year Ending |
12 Dec-09 |
15 Mar-11 |
12 Mar-12 |
12 Mar-13 |
12 Mar-14 |
5-Yr Chart Click to enlarge
|
|---|
| ASTRAZENECA PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 1,109 | 1,448 | 2,489 | 2,649 | 1,285 | |
| Low | Rs | 421 | 802 | 1,162 | 595 | 634 | |
| Sales per share (Unadj.) | Rs | 158.7 | 237.7 | 212.6 | 156.2 | 189.6 | |
| Earnings per share (Unadj.) | Rs | 23.0 | 25.7 | 7.9 | -35.8 | -0.2 | |
| Diluted earnings per share | Rs | 23.0 | 25.7 | 7.9 | -35.8 | -0.2 | |
| Cash flow per share (Unadj.) | Rs | 25.5 | 29.2 | 10.8 | -30.9 | 3.8 | |
| Dividends per share (Unadj.) | Rs | 10.00 | 10.00 | 3.50 | 0 | 0 | |
| Adj. dividends per share | Rs | 10.00 | 10.00 | 3.50 | 0.00 | 0.00 | |
| Dividend yield (eoy) | % | 1.3 | 0.9 | 0.2 | 0 | 0 | |
| Book value per share (Unadj.) | Rs | 57.8 | 71.9 | 75.7 | 39.9 | 68.6 | |
| Adj. book value per share | Rs | 57.8 | 71.9 | 75.7 | 39.9 | 68.6 | |
| Shares outstanding (eoy) | m | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | |
| Bonus/Rights/Conversions | - | - | - | - | - | ||
| Price / Sales ratio | x | 4.8 | 4.7 | 8.6 | 10.4 | 5.1 | |
| Avg P/E ratio | x | 33.2 | 43.9 | 230.8 | -45.3 | -4,712.7 | |
| P/CF ratio (eoy) | x | 30.0 | 38.6 | 168.3 | -52.5 | 249.6 | |
| Price / Book Value ratio | x | 13.2 | 15.7 | 24.1 | 40.7 | 14.0 | |
| Dividend payout | % | 43.4 | 39.0 | 44.3 | 0 | 0 | |
| Avg Mkt Cap | Rs m | 19,125 | 28,125 | 45,638 | 40,550 | 23,988 | |
| No. of employees | `000 | 1.5 | 1.7 | 1.7 | 1.6 | 1.6 | |
| Total wages/salary | Rs m | 828 | 1,505 | 1,619 | 1,485 | 1,605 | |
| Avg. sales/employee | Rs Th | 2,710.5 | 3,485.6 | 3,175.1 | 2,458.6 | 3,040.2 | |
| Avg. wages/employee | Rs Th | 565.8 | 882.7 | 967.2 | 934.9 | 1,029.2 | |
| Avg. net profit/employee | Rs Th | 393.5 | 376.1 | 118.1 | -563.8 | -3.3 | |
| ASTRAZENECA PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 3,968 | 5,943 | 5,315 | 3,904 | 4,740 | |
| Other income | Rs m | 56 | 60 | 63 | 105 | 92 | |
| Total revenues | Rs m | 4,024 | 6,003 | 5,379 | 4,009 | 4,832 | |
| Gross profit | Rs m | 891 | 1,038 | 303 | -685 | -130 | |
| Depreciation | Rs m | 61 | 88 | 73 | 123 | 101 | |
| Interest | Rs m | 1 | 0 | 0 | 0 | 0 | |
| Profit before tax | Rs m | 884 | 1,010 | 293 | -703 | -139 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 139 | |
| Tax | Rs m | 308 | 368 | 95 | 193 | 5 | |
| Profit after tax | Rs m | 576 | 641 | 198 | -895 | -5 | |
| Gross profit margin | % | 22.4 | 17.5 | 5.7 | -17.5 | -2.7 | |
| Effective tax rate | % | 34.8 | 36.5 | 32.4 | -27.4 | -3.7 | |
| Net profit margin | % | 14.5 | 10.8 | 3.7 | -22.9 | -0.1 | |
| ASTRAZENECA PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 2,006 | 2,196 | 1,946 | 1,648 | 2,726 | |
| Current liabilities | Rs m | 894 | 1,254 | 1,551 | 2,059 | 2,435 | |
| Net working cap to sales | % | 28.0 | 15.8 | 7.4 | -10.5 | 6.1 | |
| Current ratio | x | 2.2 | 1.8 | 1.3 | 0.8 | 1.1 | |
| Inventory Days | Days | 32 | 35 | 52 | 80 | 74 | |
| Debtors Days | Days | 63 | 27 | 22 | 26 | 41 | |
| Net fixed assets | Rs m | 303 | 514 | 902 | 982 | 1,035 | |
| Share capital | Rs m | 50 | 50 | 50 | 50 | 50 | |
| "Free" reserves | Rs m | 1,395 | 1,747 | 1,843 | 948 | 942 | |
| Net worth | Rs m | 1,445 | 1,797 | 1,893 | 998 | 1,716 | |
| Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Total assets | Rs m | 2,339 | 3,087 | 3,449 | 3,061 | 4,156 | |
| Interest coverage | x | 632.4 | NM | NM | NM | NM | |
| Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 1.7 | 1.9 | 1.5 | 1.3 | 1.1 | |
| Return on assets | % | 24.7 | 20.8 | 5.7 | -29.2 | -0.1 | |
| Return on equity | % | 39.9 | 35.7 | 10.4 | -89.8 | -0.3 | |
| Return on capital | % | 61.3 | 56.2 | 15.5 | -70.4 | 0 | |
| Exports to sales | % | 4.4 | 6.8 | 6.4 | 3.8 | 5.7 | |
| Imports to sales | % | 5.3 | 6.3 | 7.3 | 7.1 | 6.5 | |
| Exports (fob) | Rs m | 176 | 404 | 343 | 147 | 270 | |
| Imports (cif) | Rs m | 211 | 372 | 388 | 278 | 306 | |
| Fx inflow | Rs m | 287 | 474 | 490 | 296 | 375 | |
| Fx outflow | Rs m | 568 | 613 | 647 | 406 | 470 | |
| Net fx | Rs m | -282 | -139 | -157 | -111 | -96 | |
| ASTRAZENECA PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 326 | 645 | 387 | -60 | -8 | |
| From Investments | Rs m | 22 | -277 | -337 | -156 | -146 | |
| From Financial Activity | Rs m | -1,109 | -291 | -291 | -103 | 862 | |
| Net Cashflow | Rs m | -761 | 77 | -240 | -320 | 709 | |
ASTRAZENECA PHARMA Raw Materials Data
| ITEM | Rs m | % To R.M.C. | % To SALES |
|---|---|---|---|
| Codeine phosphate | 47.7 | 7.6 | 1.0 |
| Others | 469.6 | 74.8 | 9.7 |
| Packaging materials | 110.4 | 17.6 | 2.3 |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: D. E. Udwadia | COMP SEC: Anantha Murthy | YEAR OF INC: 1900 | BSE CODE: 506820 | FV (Rs): 2 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DR. REDDYS LAB CIPLA WYETH LTD GLENMARK PHARMA CADILA HEALTHCARE
Compare ASTRAZENECA PHARMA With: DR. REDDYS LAB CIPLA WYETH LTD GLENMARK PHARMA CADILA HEALTHCARE
Compare ASTRAZENECA PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Extends Gains; Vedanta & Yes Bank Lead the Rally(12:30 pm)
Stock markets in India are trading higher taking cues from their Asian peers, which rebounded today following a strong lead in Wall Street.
Views on news
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 212.1% (Quarterly Result Update)
Jul 20, 2018 | Updated on Jul 20, 2018For the quarter ended March 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 32 m (down 212.1% YoY). Sales on the other hand came in at Rs 2 bn (up 35.1% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Eris Lifesciences Limited (IPO)
Jun 15, 2017Exposure to high margin specialty products offers promising growth prospects.
More Views on NewsMost Popular
This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)
Aug 8, 2018Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why
Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)
Aug 9, 2018Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...
Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)
Aug 7, 2018Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.
Why HDFC Equity Fund Disappointed Its Investors(Outside View)
Aug 9, 2018Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.
HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)
Aug 8, 2018PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.
More|
| |
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA - ADCOCK INGRAM COMPARISON
COMPARE ASTRAZENECA PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.